Findings in the Area of Radiation Therapy Reported from University of Toronto (Impact of Pretreatment Tumor Growth Rate on Outcome of Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy)
By a News Reporter-Staff News Editor at Biotech Week -- Fresh data on Drugs and Therapies are presented in a new report. According to news reporting from Toronto, Canada, by NewsRx journalists, research stated, "To determine the influence of pretreatment tumor growth rate on outcomes in patients with early-stage non-small cell lung cancer (NSCLC) treated with stereotactic body radiation therapy (SBRT). A review was conducted on 160 patients with T1-T2N0M0 NSCLC treated with SBRT at single institution."
The news correspondents obtained a quote from the research from the University of Toronto, "The patient's demographic and clinical data, time interval (t) between diagnostic and planning computed tomography (CT), vital status, disease status, and cause of death were extracted from a prospectively kept database. Differences in gross tumor volume between diagnostic CT (GTV1) and planning CT (GTV2) were recorded, and growth rate was calculated by use of specific growth rate (SGR). Kaplan-Meier curves were constructed for overall survival (OS). Differences between groups were compared with a log-rank test. Multivariate analyses were performed by use of the Cox proportional hazard model with SGR and other relevant clinical factors. Cumulative incidence was calculated for local, regional, and distant failures by use of the competing risk approach and was compared with Gray's test. The median time interval between diagnostic and planning CT was 82 days. The patients were divided into 2 groups, and the median SGR was used as a cut-off. The median survival times were 38.6 and 27.7 months for the low and high SGR groups, respectively (P = .03). Eastern Cooperative Oncology Group performance status (P = .01), sex (P = .04), SGR (P = .03), and GTV2 (P = .002) were predictive for OS in multivariable Cox regression analysis and, except sex, were similarly predictive for failure-free survival (FFS). The 3-year cumulative incidences of regional failure were 19.2% and 6.0% for the high and low SGR groups, respectively (P = .047). High SGR was correlated with both poorer OS and FFS in patients with early-stage NSCLC treated with SBRT."
According to the news reporters, the research concluded: "If validated, this measurement may be useful in identifying patients most likely to benefit from adjuvant therapy after SBRT."
For more information on this research see: Impact of Pretreatment Tumor Growth Rate on Outcome of Early-Stage Lung Cancer Treated With Stereotactic Body Radiation Therapy. International Journal of Radiation Oncology Biology Physics, 2014;89(3):532-538. International Journal of Radiation Oncology Biology Physics can be contacted at: Elsevier Science Inc, 360 Park Ave South, New York, NY 10010-1710, USA (see also Drugs and Therapies).
Our news journalists report that additional information may be obtained by contacting S. Atallah, University of Toronto, Dept. of Radiat Oncol, Toronto, ON, Canada. Additional authors for this research include B.C.J. Cho, Z. Allibhai, M. Taremi, M. Giuliani, L.W. Le, A. Brade, A. Sun, A. Bezjak and A.J. Hope.
Keywords for this news article include: Canada, Toronto, Ontario, Oncology, Lung Cancer, Lung Neoplasms, Radiation Therapy, Drugs and Therapies, North and Central America
Our reports deliver fact-based news of research and discoveries from around the world. Copyright 2014, NewsRx LLC